SCHEMBL6495653

SCHEMBL6495653

Oc1cccc(CN=C(c2ccccc2)c2ccccc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 4/20 0.49
SMN1; SMN2 Q16637 1/20 0.46
OPRK1 P41145 3/20 0.46
GRIN1 Q05586 2/20 0.46
ENPP2 Q13822 1/20 0.46
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2C Q14957 1/20 0.43
GRIN3A Q8TCU5 1/20 0.43
DRD2 P14416 1/20 0.43
DRD1 P21728 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
OPRM1 P35372 2/20 0.42
OPRD1 P41143 2/20 0.42
CTBP2 P56545 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
PKM P14618 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11097294 0.89 GRIN2B (0.54) GRIN2BSMN1; SMN2GRIN1GRIN2DGRIN3B
SCHEMBL26985819 0.83 MIF (0.53) GRIN2BOPRK1GRIN1ENPP2DRD2
SCHEMBL31506291 0.83 MIF (0.53) GRIN2BOPRK1GRIN1ENPP2DRD2
SCHEMBL5075641 0.82 GRIN2B (0.63) GRIN2BGRIN1GRIN2DGRIN3BGRIN2A
SCHEMBL11094429 0.78 GRIN2B (0.57) GRIN2BGRIN1GRIN2DGRIN3BGRIN2A
SCHEMBL25484737 0.77 CYP1A2 (0.57) GRIN2BGRIN1CYP1A2CYP3A4CA12
SCHEMBL19745518 0.77 GRIN2B (0.61) GRIN2BGRIN1TAAR1KMT2ALMNA
SCHEMBL23521033 0.76 GRIN2B (0.74) GRIN2BSMN1; SMN2GRIN1ENPP2GRIN2D
SCHEMBL30389572 0.75 GRIN2B (0.53) GRIN2BGRIN1CYP1A2KMT2AMAPT
SCHEMBL14587410 0.74 GRIN2B (0.44) GRIN2BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884890-B2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2005-04-26 US disclosed